A new study has identified cellular inhibitor of apoptosis protein 1 (cIAP1), encoded by the BIRC2 gene, as a potential tumor suppressor in Ewing sarcoma, a rare and aggressive pediatric cancer driven by EWSR1::FLI1 fusion proteins. Researchers analyzed gene activity across multiple Ewing sarcoma cell lines and patient datasets, finding that higher cIAP1 levels were linked to better overall survival.
The study showed that the EWSR1::FLI1 fusion protein directly suppresses cIAP1 expression in tumor cells. When researchers restored cIAP1 to more normal levels, cancer cell growth and tumor-forming ability were significantly reduced in laboratory models.
In mouse studies, reactivating cIAP1 slowed tumor growth, reduced tumor weight, lowered cell proliferation markers, and increased tumor cell death. The findings suggest that unlike many other cancers where cIAP1 promotes survival, Ewing sarcoma may depend on suppressing cIAP1 to maintain tumor growth.
The research highlights cIAP1 as a possible future therapeutic target and prognostic marker in Ewing sarcoma.